OptiNose: Maximum Optimism
Good afternoon.
I would be glad if you subscribe to me in TradingView so you can be the first to read my new ideas. Overly grateful for your likes. In the comments, you can ask questions about the company.
Summary:
Technical analysis:
I would be glad if you subscribe to me in TradingView so you can be the first to read my new ideas. Overly grateful for your likes. In the comments, you can ask questions about the company.
Summary:
Technical analysis:
- On the chart, we can see the completion of corrective wave 2 and the emergence of impulse wave 3.
- According to the RSI indicator, we can see an uptrend, which confirms the labeling of the Elliott waves.
- On the 1D chart, we can see an open gap in the area of $6-7 per share.
- Currently, the company's shares are in the area of the downtrend breakout. In addition, Optinose shares have broken through EMA 55 and are just below EMA 89.
Fundamental Analysis:- You can read a complete fundamental analysis of the company in my analytical article in SA.
Conclusion
Considering the above factors, I believe that the growth of Optinose shares will continue.
Disclosure:
This article may not take into account all the risks and catalysts for the stocks described in it. Any part of this analytical article is provided for informational purposes only, does not constitute an individual investment recommendation, investment idea, advice, offer to buy or sold securities, or other financial instruments. The completeness and accuracy of the information in the analytical article are not guaranteed. If any fundamental criteria or events change in the future, I do not assume any obligation to update this article.
- You can read a complete fundamental analysis of the company in my analytical article in SA.
- Currently, the company's shares are in the area of the downtrend breakout. In addition, Optinose shares have broken through EMA 55 and are just below EMA 89.
- On the 1D chart, we can see an open gap in the area of $6-7 per share.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.